Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Aptose Biosciences, Inc. (APTO)

Biological Products, (no Disgnostic Substances)

https://www.aptose.com

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

251 CONSUMERS ROAD, SUITE 1105
TORONTO, A6

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/30/1992

Market Cap

8,286,861

Shares Outstanding

7,940,000

Weighted SO

7,942,363

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

CTMX --.--%

TIL --.--%

NLTX --.--%

SPRO --.--%

ASMB --.--%

FBIO --.--%

MBIO --.--%

ACHL --.--%

FBIOP --.--%

Beta

1.3580

Last Div

0.0000

Range

0.4-4.81

Chg

-0.0256

Avg Vol

75537

Mkt Cap

8286861

Exch

NASDAQ

Country

CA

Phone

16507185028

DCF Diff

-0.7556

DCF

1.2132

Div Yield

0.0000

P/S

11.6355

EV Multiple

-0.0191

P/FV

-3.5240

Div Yield %

0.0000

P/E

-0.1889

PEG

0.0120

Payout

0.0000

Current Ratio

0.7992

Quick Ratio

0.7992

Cash Ratio

0.6553

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

5779.1382

CCC

-5779.1382

Gross Margin

0.3694

Op Margin

-57.5242

Pretax Margin

-56.9777

Net Margin

-56.9777

Eff Tax Rate

0.0027

ROA

-3.7068

ROE

-56.9338

ROCE

23.2549

NI/EBT

1.0000

EBT/EBIT

0.9905

EBIT/Rev

-57.5242

Debt Ratio

0.0747

D/E

-0.3759

LT Debt/Cap

-0.2350

Total Debt/Cap

-0.6024

Int Coverage

-74.3540

CF/Debt

-45.9341

Equity Multi

-5.0317

Rec Turnover

0.0000

Pay Turnover

0.0632

Inv Turnover

0.0000

FA Turnover

0.9017

Asset Turnover

0.0651

OCF/Share

-2.2424

FCF/Share

-2.2413

Cash/Share

0.4971

OCF/Sales

-52.7535

FCF/OCF

0.9995

CF Coverage

-45.9341

ST Coverage

-93.0122

CapEx Coverage

-2092.1420

Div&CapEx Cov

-2092.1420

P/BV

-3.5240

P/B

-3.5240

P/S

11.6355

P/E

-0.1889

P/FCF

-0.2207

P/OCF

-0.2041

P/CF

-0.2041

PEG

0.0120

P/S

11.6355

EV Multiple

-0.0191

P/FV

-3.5240

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Aug 30, 20:30 Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Dec 09, 18:30 Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting GlobeNewswire Inc. Nov 30, 16:59 Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role GlobeNewswire Inc. Oct 30, 09:15 Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Revenue Product Segmentation